Edwards Lifesciences (NYSE:EW) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Edwards Lifesciences (NYSE:EW) from a peer perform rating to an outperform rating in a research report released on Wednesday, MarketBeat.com reports. They currently have $92.00 target price on the medical research company’s stock.

Several other equities analysts have also commented on the company. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their target price for the company from $90.00 to $100.00 in a report on Thursday, December 18th. Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. The Goldman Sachs Group restated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. BTIG Research restated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Citigroup reiterated a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Stock Down 0.2%

Shares of NYSE:EW opened at $80.85 on Wednesday. The company’s fifty day moving average is $81.65 and its two-hundred day moving average is $81.75. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. Edwards Lifesciences has a 1-year low of $65.94 and a 1-year high of $87.89. The stock has a market capitalization of $46.61 billion, a price-to-earnings ratio of 44.18, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same period last year, the firm posted $0.59 earnings per share. The company’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,371,239.08. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 84,398 shares of company stock worth $7,054,310. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $266,000. Westerkirk Capital Inc. bought a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $493,000. Beacon Pointe Advisors LLC increased its stake in shares of Edwards Lifesciences by 3.4% during the second quarter. Beacon Pointe Advisors LLC now owns 30,359 shares of the medical research company’s stock valued at $2,374,000 after acquiring an additional 995 shares during the period. Groupe la Francaise increased its stake in shares of Edwards Lifesciences by 719.4% during the second quarter. Groupe la Francaise now owns 19,174 shares of the medical research company’s stock valued at $1,493,000 after acquiring an additional 16,834 shares during the period. Finally, PharVision Advisers LLC bought a new stake in Edwards Lifesciences during the second quarter worth approximately $209,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.